atopic dermatitis

Biotech

Dermatitis-focused Ducentis bought by Arcutis for $30M

The British life sciences VC fund saw its first portfolio company sold off in the form of Ducentis BioTherapeutics.
James Waldron Sep 8, 2022 9:05am

Vyne to reevaluate pipeline after eczema fail uproots plans

Aug 10, 2022 11:23am

Amgen hits pause on $400M eczema bet to tweak phase 3 study

Aug 4, 2022 7:00am

Evelo Biosciences pauses dermatitis drug after trail failure

Apr 14, 2022 11:45am

Lilly’s $1B bet yields 'compelling' data on Dupixent rival

Mar 28, 2022 7:40am

J&J ends work on eczema drug, a $610M dent to ex-XBiotech asset

Feb 2, 2022 5:42pm